摘要
目的:探讨阿托伐他汀不同剂量和疗程对老年急性冠脉综合征(ACS)患者血浆可溶性细胞间粘附分子-1(sICAM-1)和可溶性E-选择素(sE-selectin)表达的影响。方法:选择ACS患者124例,随机分为3组,阿托伐他汀高剂量组(A组)、低剂量组(B组)和对照组(C组),A组和B组口服阿托伐他汀分别为20 mg/d和10mg/d,C组不服用他汀类药物,用酶联免疫吸附测定(ELISA)法分别测定3组患者治疗前,治疗4周、8周和24周后血浆sICAM和sE-选择素的浓度。结果:A组和B组患者治疗4周、8周和16周后sICAM和sE-选择素水平呈逐渐降低趋势,同治疗前比较差异均有显著性(P<0.05,<0.05,<0.01),C组治疗前、后差异无显著性(P>0.05);A组8周和24周时sICAM和sE-选择素较B组显著降低(P均<0.05)结论:阿托伐他汀具有抑制细胞粘附分子表达的作用,其作用可能与剂量和疗程有关,随剂量增加和应用时间延长而作用增强。
Objective： To explore the effects of atorvastatin in different dosage and stage on expression of plasma soluble ICAM-1 （sICAM-1） and soluble E--selectin （sE-selectin） in old patients with acute coronary syndrome （ACS）. Methods： A total of 124 patients with ACS were randomly divided into three groups including atorvastatin in high dosage group （group A）, atorvastatin in low dosage group （group B） and control group （group C）. Patients in group A and B were respectively treated with atorvastatin 20 mg and 10 mg per day for 24 weeks. Before and after treated 4, 8 and 24 weeks, the concentrations of plasma slCAM-1 and sE-selectin were measured by ELISA. Results： After 4, 8 and 24 weeks of treatment, the levels of plasma sICAM- 1 and sE selectin significantly reduced than before （P〈0.05. 〈0.05, 〈0.01） in group A and B, and there was a tendency of reduced concentrations, but in group C the difference was no statistic significance （P〉0.05）. After 8 and 24 weeks of treatment, the concentrations of sICAM- 1 and sE--selectin in group A patients were lower than that in group B （P〈0.05）. Conclusion： Atorvastatin can inhibit expression of cell adhesion molecule, which is related with dosage and stage.
出处
《心血管康复医学杂志》
CAS
2009年第2期155-157,共3页
Chinese Journal of Cardiovascular Rehabilitation Medicine
